Moderna says FDA to review its flu vaccine after reversing course
#Moderna #FDA #flu vaccine #2026-27 season #reversal #availability
📌 Key Takeaways
- Moderna plans to offer its flu vaccine in the upcoming 2026-27 season.
- The U.S. FDA reversed a prior decision that had restricted the vaccine's availability.
- The reversal allows Moderna to pursue a new review of its flu vaccine.
- The announcement was made in the context of the U.S. regulatory environment.
- The company’s goal is to provide the vaccine to the public in the upcoming flu season.
📖 Full Retelling
Moderna, a biotechnology company, announced that it will aim to make its flu vaccine available for the 2026-27 season after the U.S. Food and Drug Administration reversed its earlier decision, signaling a new review of the product.
🏷️ Themes
Pharmaceutical development, Regulatory review, Seasonal influenza, U.S. FDA policy, Vaccine distribution
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.
Read full article at source